Clinical observation of adjuvant therapy of herpes zoster by external application of Longkui

  Objective  To explore the clinical efficacy and safety of Longkui external application with western medicine in adjuvant therapy of herpes zoster.

  Methods  A total of 76 patients were randomly divided into treatment group (n=38) and control group (n=38).The control group was given dispersive tablets of famiclovir dispersible tablets, vitamin B₁ tablets and vitamin B₁₂ injection, while the treatment group was given Longkui external application on the basis of the control group, and lasted for 14 days.Visual Analogue Scale (VAS) score, sleep quality score (QS) and herpes evaluation indexes (blister-stopping time, crusting time and scab removal time) were observed before and after treatment in the two groups; the occurrence of adverse reactions after medication in two groups was analyzed.

  Results  After treatment, the VAS scores in both groups were significantly lower than before, and the treatment group was significantly lower after treatment than the control group (P < 0.05 or P < 0.01); the QS scores in both groups were significantly lower than before treatment, and the treatment group was significantly lower than the control group (P < 0.05 or P < 0.01).The time of blister-stopping, crusting and scab removal in the treatment group was significantly shorter than that in the control group (P < 0.01).There was no significantly significance in the occurrence of adverse reactions between two groups (P>0.05).

  Conclusion  Longkui external application with western medicine in adjuvant therapy of patients with herpes zoster is better than simple western medicine treatment, which can effectively relieve pain, improve the sleep quality of patients, significantly shorten the time of blister-stopping, crusting and scab removal, and has high safety as well as less adverse reactions.